Research programme: monoclonal antibody therapeutics - arGEN-X/Bird Rock Bio

Drug Profile

Research programme: monoclonal antibody therapeutics - arGEN-X/Bird Rock Bio

Alternative Names: Anti-interleukin 22 monoclonal antibody; Anti-Nav1.7 monoclonal antibody; ARGX-112; Monoclonal antibodies targeting GPCR receptors - Bird Rock Bio; RYI-018

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator arGEN-X
  • Developer arGEN-X; Bird Rock Bio
  • Class Monoclonal antibodies
  • Mechanism of Action G protein-coupled receptor modulators; Interleukin 22 receptor antagonists; Interleukin 6 inhibitors; Nav1.7-voltage-gated-sodium-channel-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Inflammation; Ovarian cancer; Pain; Renal cancer; Skin disorders

Most Recent Events

  • 14 Dec 2015 RuiYi plans a phase I trial for non-alcoholic fibrotic liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in USA
  • 21 May 2015 arGEN-X and LEO Pharma agree to collaborate on monoclonal antibody therapeutics, including ARGX 112, for inflammatory Skin disorders
  • 18 Feb 2015 arGEN-X in-licenses GS Xceed™ System technology from Lonza )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top